Results 81 to 90 of about 2,290,510 (294)

Application of Fragment-Based Drug Discovery to Versatile Targets

Frontiers in Molecular Biosciences, 2020
Fragment-based drug discovery (FBDD) is a powerful method to develop potent small-molecule compounds starting from fragments binding weakly to targets. As FBDD exhibits several advantages over high-throughput screening campaigns, it becomes an attractive
Qingxin Li
doaj   +1 more source

Covariate-assisted ranking and screening for large-scale two-sample inference [PDF]

, 2019
Two-sample multiple testing has a wide range of applications. The conventionalpractice first reduces the original observations to a vector of p-values and then chooses a cutoffto adjust for multiplicity.
Cai, T. Tony, Sun, Wenguang, Wang, Weinan   +2 more
core  

Unburied Higgs

, 2010
Many models of physics beyond the Standard Model yield exotic Higgs decays. Some of these, particularly those in which the Higgs decays to light quarks or gluons, can be very difficult to discover experimentally.
Falkowski, Adam, Krohn, David, Shelton, Jessie, Thalapillil, Arun, Wang, Lian-Tao   +4 more
core   +1 more source

Sequence determinants of RNA G‐quadruplex unfolding by Arg‐rich regions

FEBS Letters, EarlyView.
We show that Arg‐rich peptides selectively unfold RNA G‐quadruplexes, but not RNA stem‐loops or DNA/RNA duplexes. This length‐dependent activity is inhibited by acidic residues and is conserved among SR and SR‐related proteins (SRSF1, SRSF3, SRSF9, U1‐70K, and U2AF1).
Naiduwadura Ivon Upekala De Silva, Puspa Kunwar, Md Ibnul Rifat Rahman, Joanna Koryo Kwao, Nathan Lehman, Zihan Zhang, Trenton Paul, Claire Cheng, Nicholas Truex, Hui‐Ting Lee, Jun Zhang   +10 more
wiley   +1 more source

Excess Higgs Production in Neutralino Decays

, 2012
The ATLAS and CMS experiments have recently claimed discovery of a Higgs boson-like particle at ~5 sigma confidence and are beginning to test the Standard Model predictions for its production and decay. In a variety of supersymmetric models, a neutralino
A Arvanitaki, A Arvanitaki, A Azatov, A Azatov, A Birkedal, A Carmona, A Datta, A Datta, A Delgado, A Fowler, A Maloney, A Pomarol, AG Cohen, B Bhattacherjee, B Feigl, C Brust, C Brust, C Kilic, D Das, DE Kaplan, E Contreras-Campana, F Aguila del, F Aguila del, F Campos de, G Aad, G Aad, G Aad, G Aad, G Aad, G Azuelos, G Larsen, GD Kribs, GD Kribs, GD Kribs, H Baer, H Baer, H Baer, HM Lee, I Hinchliffe, J Aguilar-Saavedra, J Aguilar-Saavedra, J Alwall, J Casas, J Ellis, J Thaler, JM Butterworth, JR Ellis, JR Espinosa, JT Ruderman, K Agashe, K Babu, K Choi, K Choi, K Harigaya, K Huitu, Kiel Howe, KT Matchev, M Asano, M Baryakhtar, M Klute, M Lisanti, M Papucci, M Sher, M Son, N Craig, N Craig, N Craig, N Vignaroli, O Aharony, O Stal, P Bandyopadhyay, P Bandyopadhyay, P Bandyopadhyay, P Bandyopadhyay, P Batra, P Meade, PP Giardino, Prashant Saraswat, PW Graham, R Barbieri, R Contino, R Dermisek, R Harnik, R Kitano, S Chang, S Chatrchyan, S Chatrchyan, S Chatrchyan, S Chatrchyan, S Chatrchyan, S Chatrchyan, S Dimopoulos, S Gori, SP Martin, T Aaltonen, T Junk, T Sjöstrand, U Baur, W Beenakker, Y Kats, Z Chacko   +100 more
core   +1 more source

In Silico Lead Discovery [PDF]

, 2011
Computer-aided drug design and in silico screening have contributed to the discovery of several compounds that have either reached the market or entered clinical trials. In silico Lead Discovery is a compilation of the efforts of several experts on bioinformatics and drug design in developing the latest advances of in silico approaches for lead ...
openaire   +1 more source

Structural instability impairs function of the UDP‐xylose synthase 1 Ile181Asn variant associated with short‐stature genetic syndrome in humans

FEBS Letters, EarlyView.
The Ile181Asn variant of human UDP‐xylose synthase (hUXS1), associated with a short‐stature genetic syndrome, has previously been reported as inactive. Our findings demonstrate that Ile181Asn‐hUXS1 retains catalytic activity similar to the wild‐type but exhibits reduced stability, a looser oligomeric state, and an increased tendency to precipitate ...
Tuo Li, Pedro A. Sánchez‐Murcia, Bernd Nidetzky   +2 more
wiley   +1 more source

Introducing doubt in Bayesian model comparison [PDF]

, 2008
There are things we know, things we know we dont know, and then there are things we dont know we dont know. In this paper we address the latter two issues in a Bayesian framework, introducing the notion of doubt to quantify the degree of (dis)belief in a
Starkman, GD, Trotta, R, Vaudrevange, PM
core   +1 more source

Two-proton radioactivity

, 2008
In the first part of the present review paper, experimental results which lead to the discovery of two-proton radioactivity are reviewed. Beyond two-proton emission from nuclear ground states, we also discuss experimental studies of two-proton emission ...
Blank, Bertram, Ploszajczak, Marek
core   +3 more sources

Cell wall target fragment discovery using a low‐cost, minimal fragment library

FEBS Letters, EarlyView.
LoCoFrag100 is a fragment library made up of 100 different compounds. Similarity between the fragments is minimized and 10 different fragments are mixed into a single cocktail, which is soaked to protein crystals. These crystals are analysed by X‐ray crystallography, revealing the binding modes of the bound fragment ligands.
Kaizhou Yan, Mathew Stanley, Olawale Raimi, Andrew T. Ferenbach, Helge C Dorfmueller, Daan M. F. van Aalten   +5 more
wiley   +1 more source